{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T12:21:59Z","timestamp":1773922919915,"version":"3.50.1"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100003009","name":"Science and Technology Development Fund","doi-asserted-by":"publisher","award":["STF 12308"],"award-info":[{"award-number":["STF 12308"]}],"id":[{"id":"10.13039\/501100003009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12985-017-0753-1","type":"journal-article","created":{"date-parts":[[2017,5,2]],"date-time":"2017-05-02T13:32:17Z","timestamp":1493731937000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Hepatitis C virus management: potential impact of nanotechnology"],"prefix":"10.1186","volume":"14","author":[{"given":"Mostafa H.","family":"Elberry","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noureldien H. E.","family":"Darwish","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaker A.","family":"Mousa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,5,2]]},"reference":[{"key":"753_CR1","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/S1473-3099(05)70216-4","volume":"5","author":"CW Shepard","year":"2005","unstructured":"Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005;5:558\u201367.","journal-title":"Lancet Infect Dis."},{"key":"753_CR2","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJM200107053450107","volume":"345","author":"GM Lauer","year":"2001","unstructured":"Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001;345:41\u201352.","journal-title":"N Engl J Med."},{"key":"753_CR3","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1053\/j.gastro.2012.02.015","volume":"142","author":"EA Schaefer","year":"2012","unstructured":"Schaefer EA, Chung RT. Anti-hepatitis C virus drugs in development. Gastroenterology. 2012;142:1340\u201350. e1.","journal-title":"Gastroenterology"},{"key":"753_CR4","doi-asserted-by":"publisher","first-page":"458","DOI":"10.4065\/71.5.458","volume":"71","author":"NN Zein","year":"1996","unstructured":"Zein NN, Persing DH. Hepatitis C genotypes: current trends and future implications. Mayo Clin Proc. 1996;71:458\u201362.","journal-title":"Mayo Clin Proc"},{"key":"753_CR5","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1099\/0022-1317-81-7-1631","volume":"81","author":"R Bartenschlager","year":"2000","unstructured":"Bartenschlager R, Lohmann V. Replication of hepatitis C virus. J Gen Virol. 2000;81:1631\u201348.","journal-title":"J Gen Virol"},{"key":"753_CR6","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/hep.27259","volume":"61","author":"JP Messina","year":"2015","unstructured":"Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015;61:77\u201387.","journal-title":"Hepatology"},{"key":"753_CR7","doi-asserted-by":"publisher","first-page":"62S","DOI":"10.1002\/hep.510260711","volume":"26","author":"MJ Alter","year":"1997","unstructured":"Alter MJ. Epidemiology of hepatitis C. Hepatology. 1997;26:62S\u20135S.","journal-title":"Hepatology"},{"key":"753_CR8","doi-asserted-by":"publisher","first-page":"S93","DOI":"10.1002\/hep.1840360712","volume":"36","author":"MJ Alter","year":"2002","unstructured":"Alter MJ. Prevention of spread of hepatitis C. Hepatology. 2002;36:S93\u20138.","journal-title":"Hepatology"},{"key":"753_CR9","doi-asserted-by":"publisher","first-page":"A628","DOI":"10.1016\/j.jval.2015.09.2213","volume":"18","author":"P McEwan","year":"2015","unstructured":"McEwan P, Ward T, Webster S, Kalsekar A, Brenner M, Yuan Y. Modeling the cost-effectiveness of the all oral, direct-acting antiviral regimen daclatasvir plus sofosbuvir in patients co-infected with hepatitis C virus (HCV) and HIV. Value Health. 2015;18:A628.","journal-title":"Value Health"},{"key":"753_CR10","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrgastro.2015.184","volume":"12","author":"JM Pawlotsky","year":"2015","unstructured":"Pawlotsky JM. Therapy: avoiding treatment failures associated with HCV resistance. Nat Rev Gastroenterol Hepatol. 2015;12:673\u20134.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"753_CR11","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1038\/nbt.2020","volume":"29","author":"AD Kwong","year":"2011","unstructured":"Kwong AD, Kauffman RS, Hurter P, Mueller P. Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus. Nat Biotechnol. 2011;29:993\u20131003.","journal-title":"Nat Biotechnol"},{"issue":"Suppl 1","key":"753_CR12","doi-asserted-by":"publisher","first-page":"i36","DOI":"10.1136\/gutjnl-2012-302144","volume":"61","author":"C Welsch","year":"2012","unstructured":"Welsch C, Jesudian A, Zeuzem S, Jacobson I. New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives. Gut. 2012;61 Suppl 1:i36\u201346.","journal-title":"Gut"},{"key":"753_CR13","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1128\/JCM.05842-11","volume":"50","author":"S Fonseca-Coronado","year":"2012","unstructured":"Fonseca-Coronado S, Escobar-Gutierrez A, Ruiz-Tovar K, Cruz-Rivera MY, Rivera-Osorio P, Vazquez-Pichardo M, et al. Specific detection of naturally occurring hepatitis C virus mutants with resistance to telaprevir and boceprevir (protease inhibitors) among treatment-naive infected individuals. J Clin Microbiol. 2012;50:281\u20137.","journal-title":"J Clin Microbiol"},{"key":"753_CR14","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/1743-422X-9-57","volume":"9","author":"W Aman","year":"2012","unstructured":"Aman W, Mousa S, Shiha G, Mousa SA. Current status and future directions in the management of chronic hepatitis C. Virol J. 2012;9:57.","journal-title":"Virol J"},{"key":"753_CR15","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.pharmthera.2014.09.002","volume":"145","author":"V Belousova","year":"2015","unstructured":"Belousova V, Abd-Rabou AA, Mousa SA. Recent advances and future directions in the management of hepatitis C infections. Pharmacol Ther. 2015;145:92\u2013102.","journal-title":"Pharmacol Ther"},{"key":"753_CR16","doi-asserted-by":"publisher","first-page":"7906","DOI":"10.1166\/jnn.2010.3617","volume":"10","author":"S Singh","year":"2010","unstructured":"Singh S. Nanomedicine-nanoscale drugs and delivery systems. J Nanosci Nanotechnol. 2010;10:7906\u201318.","journal-title":"J Nanosci Nanotechnol"},{"key":"753_CR17","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.addr.2009.11.010","volume":"62","author":"A Sosnik","year":"2010","unstructured":"Sosnik A, Amiji M. Nanotechnology solutions for infectious diseases in developing nations. Preface Adv Drug Deliv Rev. 2010;62:375\u20137.","journal-title":"Preface Adv Drug Deliv Rev"},{"key":"753_CR18","doi-asserted-by":"publisher","first-page":"16921","DOI":"10.1039\/C5NR02898A","volume":"7","author":"A Lakshminarayanan","year":"2015","unstructured":"Lakshminarayanan A, Reddy BU, Raghav N, Ravi VK, Kumar A, Maiti PK, et al. A galactose-functionalized dendritic siRNA-nanovector to potentiate hepatitis C inhibition in liver cells. Nanoscale. 2015;7:16921\u201331.","journal-title":"Nanoscale"},{"key":"753_CR19","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.virusres.2007.02.022","volume":"127","author":"R Bartenschlager","year":"2007","unstructured":"Bartenschlager R, Sparacio S. Hepatitis C virus molecular clones and their replication capacity in vivo and in cell culture. Virus Res. 2007;127:195\u2013207.","journal-title":"Virus Res"},{"key":"753_CR20","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1128\/JVI.66.3.1476-1483.1992","volume":"66","author":"K Tsukiyama-Kohara","year":"1992","unstructured":"Tsukiyama-Kohara K, Iizuka N, Kohara M, Nomoto A. Internal ribosome entry site within hepatitis C virus RNA. J Virol. 1992;66:1476\u201383.","journal-title":"J Virol"},{"key":"753_CR21","doi-asserted-by":"crossref","first-page":"4665","DOI":"10.1128\/JVI.67.8.4665-4675.1993","volume":"67","author":"M Hijikata","year":"1993","unstructured":"Hijikata M, Mizushima H, Akagi T, Mori S, Kakiuchi N, Kato N, et al. Two distinct proteinase activities required for the processing of a putative nonstructural precursor protein of hepatitis C virus. J Virol. 1993;67:4665\u201375.","journal-title":"J Virol"},{"key":"753_CR22","doi-asserted-by":"publisher","first-page":"10583","DOI":"10.1073\/pnas.90.22.10583","volume":"90","author":"A Grakoui","year":"1993","unstructured":"Grakoui A, McCourt DW, Wychowski C, Feinstone SM, Rice CM. A second hepatitis C virus-encoded proteinase. Proc Natl Acad Sci U S A. 1993;90:10583\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"753_CR23","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1128\/JVI.67.7.3835-3844.1993","volume":"67","author":"R Bartenschlager","year":"1993","unstructured":"Bartenschlager R, Ahlborn-Laake L, Mous J, Jacobsen H. Nonstructural protein 3 of the hepatitis C virus encodes a serine-type proteinase required for cleavage at the NS3\/4 and NS4\/5 junctions. J Virol. 1993;67:3835\u201344.","journal-title":"J Virol"},{"key":"753_CR24","doi-asserted-by":"publisher","first-page":"9939","DOI":"10.1128\/JVI.75.20.9939-9946.2001","volume":"75","author":"M Pallaoro","year":"2001","unstructured":"Pallaoro M, Lahm A, Biasiol G, Brunetti M, Nardella C, Orsatti L, et al. Characterization of the hepatitis C virus NS2\/3 processing reaction by using a purified precursor protein. J Virol. 2001;75:9939\u201346.","journal-title":"J Virol"},{"key":"753_CR25","doi-asserted-by":"publisher","first-page":"11240","DOI":"10.1128\/JVI.01826-14","volume":"88","author":"SH Han","year":"2014","unstructured":"Han SH, Kim SJ, Kim EJ, Kim TE, Moon JS, Kim GW, et al. Phosphorylation of hepatitis C virus RNA polymerases ser29 and ser42 by protein kinase C-related kinase 2 regulates viral RNA replication. J Virol. 2014;88:11240\u201352.","journal-title":"J Virol"},{"key":"753_CR26","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.jhep.2015.09.024","volume":"64","author":"S Zeuzem","year":"2016","unstructured":"Zeuzem S, Hezode C, Bronowicki JP, Loustaud-Ratti V, Gea F, Buti M, et al. Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection. J Hepatol. 2016;64:292\u2013300.","journal-title":"J Hepatol"},{"key":"753_CR27","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.17554\/j.issn.2224-3992.2015.04.535","volume":"4","author":"G Morelli","year":"2015","unstructured":"Morelli G, Firpi R, Horne P, Peter J, Askushevich L, Vainorius M, et al. Open-label study to evaluate the safety & tolerability of telaprevir in combination with sofosbuvir in naive subjects with HCV genotype 1. J Gastroenterol Hepatol Res. 2015;4:1599\u2013604.","journal-title":"J Gastroenterol Hepatol Res"},{"key":"753_CR28","doi-asserted-by":"publisher","first-page":"S270","DOI":"10.1016\/S0168-8278(15)30168-9","volume":"62","author":"P Kwo","year":"2015","unstructured":"Kwo P, Gitlin N, Nahass R, Bernstein D, Rojter S, Schiff E, et al. A phase-3, randomised, open-label study to evaluate the efficacy and safety of 8 and 12\u00a0weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naive and-experienced patients with chronic HCV genotype 1 infection without cirrhosis: Optimist-1. J Hepatol. 2015;62:S270.","journal-title":"J Hepatol"},{"key":"753_CR29","doi-asserted-by":"publisher","unstructured":"Stedman CA, Hyland RH, Ding X, Pang PS, McHutchison JG, Gane EJ. Once daily ledipasvir\/sofosbuvir fixed-dose combination with ribavirin in patients with inherited bleeding disorders and hepatitis C genotype 1 infection. Haemophilia. 2015. doi 10.1111\/hae.12791","DOI":"10.1111\/hae.12791"},{"key":"753_CR30","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1586\/17474124.2015.1111757","volume":"9","author":"M Bourliere","year":"2015","unstructured":"Bourliere M, Adhoute X, Ansaldi C, Oules V, Benali S, Portal I, et al. Sofosbuvir plus ledipasvir in combination for the treatment of hepatitis C infection. Expert Rev Gastroenterol Hepatol. 2015;9:1483\u201394.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"753_CR31","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1002\/hep.27726","volume":"61","author":"DR Nelson","year":"2015","unstructured":"Nelson DR, Cooper JN, Lalezari JP, Lawitz E, Pockros PJ, Gitlin N, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology. 2015;61:1127\u201335.","journal-title":"Hepatology"},{"key":"753_CR32","doi-asserted-by":"publisher","first-page":"2502","DOI":"10.1016\/S0140-6736(15)60159-3","volume":"385","author":"C Hezode","year":"2015","unstructured":"Hezode C, Asselah T, Reddy KR, Hassanein T, Berenguer M, Fleischer-Stepniewska K, et al. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet. 2015;385:2502\u20139.","journal-title":"Lancet"},{"key":"753_CR33","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/S1473-3099(15)00157-7","volume":"15","author":"A Kohli","year":"2015","unstructured":"Kohli A, Kapoor R, Sims Z, Nelson A, Sidharthan S, Lam B, et al. Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study. Lancet Infect Dis. 2015;15:1049\u201354.","journal-title":"Lancet Infect Dis"},{"key":"753_CR34","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","volume":"373","author":"JJ Feld","year":"2015","unstructured":"Feld JJ, Jacobson IM, Hezode C, Asselah T, Ruane PJ, Gruener N, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015;373:2599\u2013607.","journal-title":"N Engl J Med"},{"key":"753_CR35","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1053\/j.gastro.2014.10.007","volume":"148","author":"GJ Dore","year":"2015","unstructured":"Dore GJ, Lawitz E, Hezode C, Shafran SD, Ramji A, Tatum HA, et al. Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection. Gastroenterology. 2015;148:355\u201366. e1.","journal-title":"Gastroenterology"},{"key":"753_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7326\/M15-0785","volume":"163","author":"S Zeuzem","year":"2015","unstructured":"Zeuzem S, Ghalib R, Reddy KR, Pockros PJ, Ben Ari Z, Zhao Y, et al. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: A randomized trial. Ann Intern Med. 2015;163:1\u201313.","journal-title":"Ann Intern Med."},{"key":"753_CR37","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1016\/S0168-8278(14)60010-6","volume":"1","author":"R Esteban","year":"2014","unstructured":"Esteban R, Nyberg L, Lalezari J, Ni L, Doehle B, Kanwar B, et al. Successful retreatment with sofosbuvir-containing regimens for HCV genotype 2 or 3 infected patients who failed prior sofosbuvir plus ribavarin therapy. J Hepatology. 2014;1:S4\u20135.","journal-title":"J Hepatology"},{"key":"753_CR38","doi-asserted-by":"publisher","first-page":"851","DOI":"10.15252\/emmm.201100899","volume":"6","author":"E Rooij van","year":"2014","unstructured":"van Rooij E, Kauppinen S. Development of microRNA therapeutics is coming of age. EMBO Mol Med. 2014;6:851\u201364.","journal-title":"EMBO Mol Med"},{"key":"753_CR39","doi-asserted-by":"publisher","first-page":"4230","DOI":"10.1093\/nar\/gkt075","volume":"41","author":"SA Mortimer","year":"2013","unstructured":"Mortimer SA, Doudna JA. Unconventional miR-122 binding stabilizes the HCV genome by forming a trimolecular RNA structure. Nucleic Acids Research. 2013;41:4230\u201340.","journal-title":"Nucleic Acids Research."},{"key":"753_CR40","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1073\/pnas.1112263109","volume":"109","author":"T Shimakami","year":"2012","unstructured":"Shimakami T, Yamane D, Jangra RK, Kempf BJ, Spaniel C, Barton DJ, et al. Stabilization of hepatitis C virus RNA by an Ago2-miR-122 complex. Proc Natl Acad Sci USA. 2012;109:941\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"753_CR41","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1126\/science.1178178","volume":"327","author":"RE Lanford","year":"2010","unstructured":"Lanford RE, Hildebrandt-Eriksen ES, Petri A, Persson R, Lindow M, Munk ME, et al. Therapeutic Silencing of MicroRNA-122 in primates with chronic Hepatitis C virus infection. Science. 2010;327:198\u2013201.","journal-title":"Science"},{"key":"753_CR42","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1056\/NEJMoa1209026","volume":"368","author":"HL Janssen","year":"2013","unstructured":"Janssen HL, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K, et al. Treatment of HCV infection by targeting microRNA. N Engl J Med. 2013;368:1685\u201394.","journal-title":"N Engl J Med"},{"key":"753_CR43","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1002\/hep.510260231","volume":"26","author":"HC Bodenheimer Jr","year":"1997","unstructured":"Bodenheimer Jr HC, Lindsay KL, Davis GL, Lewis JH, Thung SN, Seeff LB. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology. 1997;26:473\u20137.","journal-title":"Hepatology"},{"key":"753_CR44","doi-asserted-by":"publisher","first-page":"4075","DOI":"10.1073\/pnas.73.11.4075","volume":"73","author":"R Schekman","year":"1976","unstructured":"Schekman R, Singer SJ. Clustering and endocytosis of membrane receptors can be induced in mature erythrocytes of neonatal but not adult humans. Proc Natl Acad Sci USA. 1976;73:4075\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"753_CR45","doi-asserted-by":"publisher","first-page":"4353","DOI":"10.1021\/es0522635","volume":"40","author":"BM Rothen-Rutishauser","year":"2006","unstructured":"Rothen-Rutishauser BM, Schurch S, Haenni B, Kapp N, Gehr P. Interaction of fine particles and nanoparticles with red blood cells visualized with advanced microscopic techniques. Environ Sci Technol. 2006;40:4353\u20139.","journal-title":"Environ Sci Technol"},{"key":"753_CR46","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/jvh.12166_18","volume":"20","author":"Y Abo\u2010zeid","year":"2013","unstructured":"Abo\u2010zeid Y, Irving W, Thomson B, Mantovani G, Garnett M. P19: Ribavirin\u2010boronic acid loaded nanoparticles: a possible route to improve hepatitis C treatment. J Viral Hepatitis. 2013;20:26\u20137.","journal-title":"J Viral Hepatitis"},{"key":"753_CR47","doi-asserted-by":"publisher","first-page":"4005","DOI":"10.1002\/jps.24219","volume":"103","author":"T Ishihara","year":"2014","unstructured":"Ishihara T, Kaneko K, Ishihara T, Mizushima T. Development of biodegradable nanoparticles for liver-specific ribavirin delivery. J Pharm Sci. 2014;103:4005\u201311.","journal-title":"J Pharm Sci."},{"key":"753_CR48","first-page":"903","volume":"10","author":"KR Jyothi","year":"2015","unstructured":"Jyothi KR, Beloor J, Jo A, Nguyen MN, Choi TG, Kim JH, et al. Liver-targeted cyclosporine A-encapsulated poly (lactic-co-glycolic) acid nanoparticles inhibit hepatitis C virus replication. Int J Nanomedicine. 2015;10:903\u201321.","journal-title":"Int J Nanomedicine"},{"key":"753_CR49","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1099\/vir.0.79896-0","volume":"85","author":"X Jiao","year":"2004","unstructured":"Jiao X, Wang RY, Qiu Q, Alter HJ, Shih JW. Enhanced hepatitis C virus NS3 specific Th1 immune responses induced by co-delivery of protein antigen and CpG with cationic liposomes. J Gen Virol. 2004;85:1545\u201353.","journal-title":"J Gen Virol"},{"key":"753_CR50","doi-asserted-by":"publisher","first-page":"5525","DOI":"10.1073\/pnas.0801388105","volume":"105","author":"MD Bobardt","year":"2008","unstructured":"Bobardt MD, Cheng G, de Witte L, Selvarajah S, Chatterji U, Sanders-Beer BE, et al. Hepatitis C virus NS5A anchor peptide disrupts human immunodeficiency virus. Proc Natl Acad Sci U S A. 2008;105:5525\u201330.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"753_CR51","doi-asserted-by":"publisher","first-page":"3088","DOI":"10.1073\/pnas.0712380105","volume":"105","author":"G Cheng","year":"2008","unstructured":"Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, et al. A virocidal amphipathic \u03b1-helical peptide that inhibits hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A. 2008;105:3088\u201393.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"753_CR52","doi-asserted-by":"publisher","first-page":"3846","DOI":"10.1016\/j.biomaterials.2013.01.026","volume":"34","author":"J Zhang","year":"2013","unstructured":"Zhang J, Mulvenon A, Makarov E, Wagoner J, Knibbe J, Kim JO, et al. Antiviral peptide nanocomplexes as a potential therapeutic modality for HIV\/HCV co-infection. Biomaterials. 2013;34:3846\u201357.","journal-title":"Biomaterials"},{"key":"753_CR53","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.biomaterials.2015.08.014","volume":"70","author":"J Zhang","year":"2015","unstructured":"Zhang J, Garrison JC, Poluektova LY, Bronich TK, Osna NA. Liver-targeted antiviral peptide nanocomplexes as potential anti-HCV therapeutics. Biomaterials. 2015;70:37\u201347.","journal-title":"Biomaterials"},{"key":"753_CR54","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1128\/MMBR.67.4.657-685.2003","volume":"67","author":"N Agrawal","year":"2003","unstructured":"Agrawal N, Dasaradhi PV, Mohmmed A, Malhotra P, Bhatnagar RK, Mukherjee SK. RNA interference: biology, mechanism, and applications. Microbiol Mol Biol Rev. 2003;67:657\u201385.","journal-title":"Microbiol Mol Biol Rev"},{"key":"753_CR55","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1073\/pnas.252783999","volume":"100","author":"SB Kapadia","year":"2003","unstructured":"Kapadia SB, Brideau-Andersen A, Chisari FV. Interference of hepatitis C virus RNA replication by short interfering RNAs. Proc Natl Acad Sci U S A. 2003;100:2014\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"753_CR56","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.jconrel.2006.07.021","volume":"115","author":"H Katas","year":"2006","unstructured":"Katas H, Alpar HO. Development and characterisation of chitosan nanoparticles for siRNA delivery. J Control Release. 2006;115:216\u201325.","journal-title":"J Control Release"},{"key":"753_CR57","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ijpharm.2014.12.047","volume":"479","author":"J Torrecilla","year":"2015","unstructured":"Torrecilla J, del Pozo-Rodriguez A, Apaolaza PS, Solinis MA, Rodriguez-Gascon A. Solid lipid nanoparticles as non-viral vector for the treatment of chronic hepatitis C by RNA interference. Int J Pharm. 2015;479:181\u20138.","journal-title":"Int J Pharm"},{"key":"753_CR58","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.jviromet.2015.06.010","volume":"222","author":"X Hang","year":"2015","unstructured":"Hang X, Peng H, Song H, Qi Z, Miao X, Xu W. Antiviral activity of cuprous oxide nanoparticles against hepatitis C virus in vitro. J Virol Methods. 2015;222:150\u20137.","journal-title":"J Virol Methods"},{"key":"753_CR59","doi-asserted-by":"publisher","first-page":"4262","DOI":"10.1073\/pnas.94.9.4262","volume":"94","author":"SW Santoro","year":"1997","unstructured":"Santoro SW, Joyce GF. A general purpose RNA-cleaving DNA enzyme. Proc Natl Acad Sci U S A. 1997;94:4262\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"753_CR60","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1038\/sj.mt.6300231","volume":"15","author":"MB Appaiahgari","year":"2007","unstructured":"Appaiahgari MB, Vrati S. DNAzyme-mediated inhibition of Japanese encephalitis virus replication in mouse brain. Mol Ther. 2007;15:1593\u20139.","journal-title":"Mol Ther"},{"key":"753_CR61","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.1016\/j.biomaterials.2011.12.015","volume":"33","author":"SR Ryoo","year":"2012","unstructured":"Ryoo SR, Jang H, Kim KS, Lee B, Kim KB, Kim YK, et al. Functional delivery of DNAzyme with iron oxide nanoparticles for hepatitis C virus gene knockdown. Biomaterials. 2012;33:2754\u201361.","journal-title":"Biomaterials"},{"key":"753_CR62","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/978-3-642-27426-8_17","volume-title":"From nucleic acids sequences to molecular medicine","author":"D-H Min","year":"2012","unstructured":"Min D-H, Kim D-E. Suppression of hepatitis C viral genome replication with RNA-cleaving deoxyribozyme. In: Erdmann VA, Barciszewski J, editors. From nucleic acids sequences to molecular medicine. Heidelburg: Springer; 2012. p. 429\u201352."},{"key":"753_CR63","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1053\/j.gastro.2009.11.053","volume":"138","author":"A Ahmed-Belkacem","year":"2010","unstructured":"Ahmed-Belkacem A, Ahnou N, Barbotte L, Wychowski C, Pallier C, Brillet R, et al. Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase. Gastroenterology. 2010;138:1112\u201322.","journal-title":"Gastroenterology"},{"key":"753_CR64","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1002\/hep.23587","volume":"51","author":"J Wagoner","year":"2010","unstructured":"Wagoner J, Negash A, Kane OJ, Martinez LE, Nahmias Y, Bourne N, et al. Multiple effects of silymarin on the hepatitis C virus lifecycle. Hepatology. 2010;51:1912\u201321.","journal-title":"Hepatology"},{"key":"753_CR65","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1166\/jbn.2016.2161","volume":"12","author":"M Ripoli","year":"2016","unstructured":"Ripoli M, Angelico R, Sacco P, Ceglie A, Mangia A. Phytoliposome-based silibinin delivery system as a promising strategy to prevent hepatitis C virus infection. J Biomedical Nanotech. 2016;12:770\u201380.","journal-title":"J Biomedical Nanotech"},{"key":"753_CR66","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1126\/science.2200121","volume":"249","author":"C Tuerk","year":"1990","unstructured":"Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science. 1990;249:505\u201310.","journal-title":"Science"},{"key":"753_CR67","doi-asserted-by":"publisher","first-page":"79433","DOI":"10.1039\/C5RA12209K","volume":"5","author":"N Delaviz","year":"2015","unstructured":"Delaviz N, Gill P, Ajami A, Aarabi M. Aptamer-conjugated magnetic nanoparticles for the efficient removal of HCV particles from human plasma samples. RSC Advances. 2015;5:79433\u20139.","journal-title":"RSC Advances"},{"key":"753_CR68","unstructured":"Mousa SA. Nano-targeted delivery of protease, polymerase inhibitors with or without immune modulators in the treatment of hepatitis C. US Patent 9,597,351; 2017."},{"key":"753_CR69","unstructured":"Mousa SA. Composition and method of use for combinations of anti-viral protease, polymerase inhibitors and natural bioactive compounds in the treatment of hepatitis C infection. 2016. US Patent application 20160346308."},{"key":"753_CR70","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.nano.2016.08.018","volume":"13","author":"D Sepulveda-Crespo","year":"2017","unstructured":"Sepulveda-Crespo D, Jimenez JL, Gomez R, De La Mata FJ, Majano PL, Munoz-Fernandez MA, et al. Polyanionic carbosilane dendrimers prevent hepatitis C virus infection in cell culture. Nanomedicine. 2017;13:49\u201358.","journal-title":"Nanomedicine"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-017-0753-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T19:04:05Z","timestamp":1602011045000},"score":1,"resource":{"primary":{"URL":"http:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-017-0753-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,2]]},"references-count":70,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["753"],"URL":"https:\/\/doi.org\/10.1186\/s12985-017-0753-1","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,2]]},"article-number":"88"}}